Vor Biopharma Inc.
NASDAQ:VORBiotechnology
-$0.34 today
- Market cap
- $966.13M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$2,053.13
Volume 0.79M
Average 1.07M
VOR Sales of Investments
Cash received from selling or redeeming investments.
Vor Biopharma Inc.NASDAQ: VOR
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments growth accelerates
Q1 FY2026 sales of investments of $13.31M rose 1331000.0% year over year, ahead of the -65.5% change in trailing-twelve-month sales of investments. Sequentially, it rose 166.2% from the prior quarter. Over 3 fiscal years it compounded at -48.9% a year.
Context
- Sales of investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1331000.0% holds above the trailing-twelve-month pace of -65.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 5M USD
- Year-over-year change
- -95.3%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5M | -95.3% |
| FY2024 | 2024-12-31 | 107M | -27.2% |
| FY2023 | 2023-12-31 | 147M | +291.4% |
| FY2022 | 2022-12-31 | 37.56M | — |
| FY2021 | 2021-12-31 | 0 | — |
Sales of Investments vs competitors
How VOR compares with its peers on the latest reported figures
- VOR's LTM Mar 2026 sales of investments of $18.31M is the smallest of the 10 companies compared; the peer median is $335.26M.
- Its year-over-year change of -65.5% is the 9th highest of 10, against a peer median of +2.6%.
- Over three fiscal years its annual growth of -48.9% compares with a peer median of -5.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.12B | +3.3% | -5.4% | 4449.2% | |
| LTM Mar 2026 | $981.03M | +2.6% | +17.3% | 1484.3% | |
| LTM Mar 2026 | $521.77M | +2508.8% | — | 563.5% | |
| LTM Mar 2026 | $364.75M | +0.0% | +11.7% | — | |
| LTM Mar 2026 | $335.26M | +13.7% | +11.1% | — | |
| LTM Mar 2026 | $271.96M | -14.9% | -19.9% | 4305.9% | |
| LTM Mar 2026 | $143.66M | +25.2% | — | — | |
| LTM Mar 2026 | $83.46M | -65.5% | -46.9% | — | |
| LTM Mar 2026 | $82.51M | -64.2% | -31.5% | 213.2% | |
| LTM Mar 2026 | $18.31M | -65.5% | -48.9% | — | |
| Peer median (excluding VOR) | $335.26M | +2.6% | -5.4% | 1484.3% | |
Competitors are the stored peer set for VOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (68.9M) | (92.09M) | (117.86M) | (116.91M) | (695.98M) |
| Depreciation & Amortization | 1.43M | 2.53M | 3.49M | 3.53M | 2.89M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.32M | 10.7M | 13.36M | 9.85M | 18.91M |
| Change in Working Capital | (9.19M) | (12.69M) | 650K | 5K | 10.21M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 405K | 0 | 2.85M | 2.24M | 0 |
| Other Working Capital | (9.59M) | (12.69M) | (2.2M) | (2.24M) | 10.21M |
| Other Non-Cash Items | 3.19M | 6.42M | 67K | 3.87M | 521.26M |
| Operating Cash Flow | (69.14M) | (85.14M) | (100.29M) | (99.66M) | (142.71M) |
| Capital Expenditures | (3.89M) | (8.46M) | (1.07M) | (229K) | (941K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (87.76M) | (123.19M) | (74.92M) | (9.91M) | (53.66M) |
| Sales of Investments | 0 | 37.56M | 147M | 107M | 5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 799K |
| Investing Cash Flow | (91.65M) | (94.09M) | 71.01M | 96.86M | (48.8M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 189.2M | 115.98M | 4.58M | 55.83M | 505.13M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.66M) | 1.17M | (1.64M) | (2.43M) | (1.33M) |
| Financing Cash Flow | 232.91M | 117.14M | 2.94M | 53.39M | 503.81M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 72.12M | (62.1M) | (26.35M) | 50.59M | 312.29M |
| Free Cash Flow | (73.04M) | (93.61M) | (101.36M) | (99.89M) | (143.65M) |
Vor Biopharma Inc.
NASDAQ:VOR
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.